616.44
Medpace Holdings Inc stock is traded at $616.44, with a volume of 207.41K.
It is down -0.65% in the last 24 hours and up +6.56% over the past month.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
See More
Previous Close:
$620.48
Open:
$616.99
24h Volume:
207.41K
Relative Volume:
0.71
Market Cap:
$17.21B
Revenue:
$2.68B
Net Income/Loss:
$460.40M
P/E Ratio:
38.78
EPS:
15.8963
Net Cash Flow:
$711.00M
1W Performance:
+5.14%
1M Performance:
+6.56%
6M Performance:
+35.89%
1Y Performance:
+25.61%
Medpace Holdings Inc Stock (MEDP) Company Profile
Name
Medpace Holdings Inc
Sector
Industry
Phone
(513) 579-9911
Address
5375 MEDPACE WAY, CINCINNATI, OH
Compare MEDP vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MEDP
Medpace Holdings Inc
|
616.44 | 16.40B | 2.68B | 460.40M | 711.00M | 15.90 |
|
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-18-26 | Upgrade | TD Cowen | Sell → Hold |
| Feb-13-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-10-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-02-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Sep-03-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-29-25 | Downgrade | UBS | Neutral → Sell |
| Jul-23-25 | Downgrade | TD Cowen | Hold → Sell |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Apr-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-24-25 | Initiated | Leerink Partners | Market Perform |
| Oct-23-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-27-24 | Downgrade | UBS | Buy → Neutral |
| Sep-25-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-24 | Initiated | Truist | Hold |
| May-29-24 | Initiated | TD Cowen | Buy |
| May-28-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-24 | Initiated | Deutsche Bank | Hold |
| Feb-15-24 | Upgrade | UBS | Neutral → Buy |
| Oct-24-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-08-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-27-22 | Upgrade | UBS | Sell → Neutral |
| Sep-07-22 | Initiated | UBS | Sell |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Oct-02-20 | Upgrade | Truist | Hold → Buy |
| Jun-08-20 | Upgrade | Robert W. Baird | Underperform → Neutral |
| May-13-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Apr-30-20 | Upgrade | SunTrust | Sell → Hold |
| Apr-20-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Mar-17-20 | Downgrade | SunTrust | Hold → Sell |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Oct-31-18 | Upgrade | SunTrust | Hold → Buy |
| Sep-17-18 | Initiated | SunTrust | Hold |
| Jul-31-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-01-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-29-17 | Initiated | Raymond James | Mkt Perform |
| Jul-10-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
View All
Medpace Holdings Inc Stock (MEDP) Latest News
Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 5 Years - Benzinga
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Reach Out - ACCESS Newswire
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Medpace Holdings, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMEDP - Eastern Progress
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky - Eastern Progress
Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - Eastern Progress
Medpace Holdings, Inc. (MEDP) Stock Analysis: Evaluating the Healthcare Giant’s Growth Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Medpace Holdings Inc. (MEDP) Key Financial Ratios – Valuation, Profitability & More - Value Research
Medpace Holdings, Inc. (MEDP), Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Medpace Holdings, Inc. (MEDP), Investigation: Bronstein, Gewirtz - The National Law Review
President & CEO Of Medpace Holdings Makes $403K Sale - benzinga.com
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term - Eastern Progress
Medpace Holdings Inc. (MEDP) Peer Comparison – Compare with Others - valueresearchonline.com
Medpace Holdings Insider Sold Shares Worth $403,176, According to a Recent SEC Filing - marketscreener.com
Medpace Holdings (MEDP) CEO sells 650 shares near $620 - Stock Titan
Medpace Holdings, Inc. (MEDP) Stock Analysis: Evaluating Its Robust Revenue Growth and Market Position - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Medpace Holdings (MEDP) director exercises options, sells 3,858 shares - Stock Titan
President & CEO At Medpace Holdings Sells $2.90M Of Stock - Benzinga
Medpace (MEDP) CEO sells 4,673 shares near $620 in open-market trades - Stock Titan
Medpace (MEDP): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Medpace (NASDAQ: MEDP) director plans 3,858-share sale after option exercise - Stock Titan
What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock - The Globe and Mail
Medpace (NASDAQ: MEDP) insider sells 15,978 shares in August trades - Stock Titan
Medpace (MEDP) CFO exercises options, sells 3,400 shares - Stock Titan
Don't Ignore The Insider Selling In Medpace Holdings - webull.com
Medpace (MEDP) Director Brian Carley Sells 5,000 Shares - GuruFocus
Medpace (NASDAQ:MEDP) Director Sells $4,414,590.45 in Stock - MarketBeat
Brian Carley Sells 5,000 Shares of Medpace (NASDAQ:MEDP) Stock - MarketBeat
Medpace (NASDAQ:MEDP) CEO August Troendle Sells 15,609 Shares of Stock - MarketBeat
August Troendle Sells 27,174 Shares of Medpace (NASDAQ:MEDP) Stock - MarketBeat
Medpace Holdings CEO August J. Troendle Executes Two-Day Stock Sale - Kalkine Media
Medpace Holdings (MEDP) CEO sells shares in $601–$626 trades - Stock Titan
Medpace (NASDAQ: MEDP) director sells 5,000 shares outside plan - Stock Titan
Medpace (MEDP) director sells 7,283 shares after option exercise - Stock Titan
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report? - Yahoo Finance
Analyst recommendations: Equifax, Medpace Holdings, Applied Materials, PayPal, Moderna… - marketscreener.com
BlackRock Inc. Acquires Shares of 2,498,248 Medpace Holdings, Inc. $MEDP - MarketBeat
Medpace (NASDAQ: MEDP) officer to sell 3,400 shares of stock - Stock Titan
Madison Asset Management LLC Invests $128.96 Million in Medpace Holdings, Inc. $MEDP - MarketBeat
NewEdge Wealth LLC Invests $27.51 Million in Medpace Holdings, Inc. $MEDP - MarketBeat
Meeder Advisory Services Inc. Invests $998,000 in Medpace Holdings, Inc. $MEDP - MarketBeat
Abacus FCF Advisors LLC Invests $6.63 Million in Medpace Holdings, Inc. $MEDP - MarketBeat
Medpace Holdings Inc (MEDP) Stock Up 3.0% but GF Value Says Over - GuruFocus
Medpace (NASDAQ: MEDP) director plans $3.0M stock sale - Stock Titan
Medpace (NASDAQ: MEDP) director lines up 7,283-share Rule 144 sale - Stock Titan
Oxbow Advisors LLC Purchases New Stake in Medpace Holdings, Inc. $MEDP - MarketBeat
Pallas Capital Advisors LLC Invests $1.13 Million in Medpace Holdings, Inc. $MEDP - MarketBeat
Summit Creek Advisors LLC Invests $3.42 Million in Medpace Holdings, Inc. $MEDP - MarketBeat
Medpace Holdings Inc Stock (MEDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Medpace Holdings Inc Stock (MEDP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kraft Robert O. | Director |
Aug 26 '26 |
Option Exercise |
84.36 |
3,858 |
325,461 |
4,813 |
| Kraft Robert O. | Director |
Aug 26 '26 |
Sale |
617.81 |
3,858 |
2,383,511 |
955 |
| Troendle August J. | President & CEO |
Aug 26 '26 |
Sale |
620.03 |
4,000 |
2,480,120 |
540,544 |
| Troendle August J. | President & CEO |
Aug 25 '26 |
Sale |
620.38 |
673 |
417,516 |
544,544 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):